Latest / Powering the Future Within / Episode 15: "Making it Look Routine": A Cardiac Surgeon’s Mission to Transform Open Heart Surgery
Transcript
- speaker-0: Welcome to Powering the Future Within, the podcast where we explore the breakthroughs shaping the future of MedTech. I'm Omari Bauchknight, CEO of ResidentLake Medical. Each episode, we speak with a leader who is driving the next wave of medical innovation, advancing technologies that are smarter, less invasive, and more connected than ever before. This is where the future of health takes shape. Let's dive in. Today's guest is Dr. Megan Helder, a cardiac surgeon and the CEO of Octon Health. At Octin Health, doctor Helda Helder is working to bring new innovations to patients with serious cardiovascular disease. Dr. Helder has spent her career in the operating room, treating some of the most complex and high risk cardiac conditions. But what makes her journey particularly unique is Is that she is simultaneously translating clinical insight into technologies that can scale and advance the standard of care in cardiac surgery. Megana, welcome to Power in the Future Within. speaker-1: Thank you so much for that kind introduction, Amari. I'm excited to be here and ⁓ talk about all things cardiac surgery. speaker-0: All things cardiac surgery. And really excited to to have you on. ⁓ from what I understand, you understood from a very early age that you wanted to become a cardiac surgeon from the age of five, is is that right? speaker-1: Pretty close. ⁓ yeah, as we were talking about, I was ⁓ born and raised in Hyderabad, India. and maybe getting a little bit off ⁓ off topic here, but very conservative family. Grandparents encouraged an arranged marriage for my mother when she was nineteen. And very excited about it and then I was born at twenty and my grandmother decided she was too young to raise me. ⁓ and so I kind of got taken away for the first five years of my life and ⁓ had an amazing childhood with grandparents. So incredibly spoiled. So it was a very imprinting day in my life ⁓ when my grandfather got admitted to the hospital. ⁓ and he was admitted with a liver abscess at the time. And I just remember him being in the hospital for days and days and being sad I couldn't play with him. And then a surgeon came in the room, took him to the operating room, and the next day he was back to his old self. ⁓ and that was kind of it for me. I wanted to be a surgeon from that day forward. And I was lucky enough ⁓ to have supporters as I was going growing up, ⁓ that I found my way into a cardiac surgical operating room when I was an eighth grader. And I got to hold a heart as an eighth grader. And that was also a game over situation. There was no other career that I was gonna live up to being able to hold and work on ⁓ and see people's hearts for a living. Yeah, that's kind of how my life has evolved. I've been very stubborn about it. Some may call it persistent. Father-in-law calls it being stubborn. speaker-0: Talk about such a powerful impression. So you have this person who means so much in your life, who appears to have a condition that's very challenging, has to leave home, be in the hospital for an extended period of time, has surgery and is restored. That must have been very motivating and compelling. And then to have an experience where you can actually feel, touch, see a human heart at the age of eight. Well, I can only imagine how how compelling that must have been. speaker-1: Yeah. Yeah. ⁓ and I think it was also one of those things that set me up ⁓ at odds with the way that most people thought ⁓ during that time, especially in India. ⁓ when you when you talk about surgery, it is this incredibly dangerous thing that is a last resort. ⁓ and people didn't think about it, at least you know, w how I grew up as a life-saving measure. Right. ⁓ and and so d it I think from a young age I was forced to kind of explain away why I wanted to do what I thought I wanted to do. ⁓ and I think that was also very important for how I view most things in general. speaker-0: Wow. We we didn't talk about it before, but just several months ago there was a family member who had to have cardiac surgery in India. They had to have a valve replaced. And you're right, the the tenor of the conversation, obviously it's always a serious condition and requires serious intervention, but there's just a whole level more would say anxiety and angst, ⁓ also related to the fact that a lot of times families have to pull money together. to be able to support these procedures there. Access to innovation in some cases can be challenging. And I also think access to information ⁓ can be challenging. And it seems like some of those experiences you've brought really together here and bring really a level of empathy to your patients that is probably higher than than what most surgeons bring. speaker-1: ⁓ you're absolutely right. And I think kind of anybody with close ties outside of high resource countries has a story like ours. ⁓ I have a similar ⁓ so my grandfather, the same grandfather actually had five other siblings and all of them genetics, right? Cardiac disease and needed a valve replaced. ⁓ my grandfather had a taver. lucky enough that he was here in the United States was with me. We actually diagnosed him the minute he kind of stepped into my mud room when he came to visit. ⁓ he was just much more sh yeah, he was just short of breath and I'd never seen him be that short of breath before. ⁓ so the the second day he was in town, he got an echo and diagnosed with aortic stenosis and ended up getting a taver, I think two months later. and maybe to contrast that, right, to his younger brother actually, who had aortic stenosis and coronary artery disease in India, probably in better shape ⁓ than my grandfather, and was told he couldn't have open cardiac surgery because i he was too risky and was told the only way he could get a taver is if he pulled together just an incredible amount of money. and ⁓ he ended up passing without any intervention. ⁓ so even in our family really seeing the difference ⁓ that access of care, ⁓ financial resources can bring and the way that you have to ⁓ you you have to kind of come to terms with that ⁓ has really been a motivating force for me. ⁓ that that is very in line kind of with Octon and ⁓ just even our kind of flagship device, kind of what I hope it will do for surgeons and for people. speaker-0: Yeah, access to care is such an important topic across geographies and even within countries, even within the U.S. differences in terms of of access to care. But what a full circle moment to have your grandfather in the US and to be diagnosed that quickly ba based on your training, and then to receive a TABR, which is a transcatheter aortic valve replacement, and one of the most important innovations. in the field of aortic surgery over the last ⁓ dec over the last decades. speaker-1: Yeah. Absolutely. Yeah. It was ⁓ it was nice to kind of put the put the hard work he had put into me to good use for his quality of life. Right. speaker-0: Yeah, I guess and he you probably r recognized that it all paid off. So let's talk about octin health, ⁓ which also interestingly is also focused on treatment of aortic diseases. What was the key observation that inspired the company's formation? speaker-1: Yeah, absolutely. Thank you for asking. So I am a practicing cardiac surgeon in Minneapolis. And ⁓ in November of twenty twenty-three, I was actually on call for that week by myself for Thanksgiving week. And we had four patients in a row come in with an aortic dissection, which is rare, ⁓ kind of at the level of our ⁓ just the volume of our hospital. In the fourth patient, was again kind of just a very one of those moments I said, we have to do better. And a ⁓ little bit to understand these operations require what we call deep hypothermic circulatory arrest. So it's different than kind of routine cardiac surgery. We place a patient on bypass like we do for every other cardiac surgical operation, but in this case, we actually use the bypass machine to cool down a patient to 18 degrees Celsius and then stop all the blood flow going to the body and the brain. So something called complete circulatory arrest. So this isn't stopping the heart, it's taking out all the blood flow in the body. And then We remove the portion of the aorta that's diseased and then put them back on bypass after it's repaired. And you're on bypass for a significant period of time, sometimes two and a half to three hours, rewarming the patient. And while you're rewarming, you know, there's eight of us in an operating room sitting there twiddling our thumbs or talking just talking because there's nothing else you can do during that time. But here is a patient. that now has undergone an eight to ten hour operation, long times on bypass, and twenty to ninety minutes of that was without any blood flow going to organs. Yeah. And so you can imagine why patients don't do well after going through something like that. And that patient in November of twenty twenty three, like I said, it was my fourth patient. I'd had three other patients I'd operated on that week upstairs kind of through the same thing that weren't doing well. I couldn't leave her in the operating room and I couldn't go take care of them. And at the end of that case, I'm it was one thirty in the morning. I was about to go home and sleep. And I turned back around and ⁓ you know, got went trash diving essentially. And and ⁓ you know, got home, super glued things together, drilled some holes, put it in a garden hose that I called the aorta, and essentially found a solution to not have to do circulatory arrest. So allowed for shunting of the blood flow from the bypass machine to the body's organs while being able to cut open the aorta and C, which is the main anatomic constraint. ⁓ And that's how Octon Health well, that's how the Elica device was created. ⁓ and then ⁓ you know, I was very naive and maybe optimistic is a good way to say it. ⁓ my husband's an attorney, so he said, Before you talk to anybody, put this, you know, ⁓ make sure you have some IP. So I listened and I did. And then ⁓ I went to a large strategic ⁓ And I said, Will you help me make this? And I think that was my pitch. Will you help me make this? And they smiled and in a very nice way said, That's not how it works anymore. You have to go make it. Show us that it works and maybe we'll buy it from you. And that was January of twenty twenty four. And I spent a few months just deciding is this something I'm going to do? Right. I wasn't associated with an academic institution. I I didn't know, you know, left from right on how to do this. but it decided with my family's support that we were essentially gonna self fund a prototype with no other intentions, no other I just wanted to see if we could build something that worked. ⁓ And it did. ⁓ we found a mechanical engineer in Minnesota, ⁓ that built kind of our first working prototype for us, ⁓ had the chance to show this to lots and lots of surgeons. We're now, you know, over a hundred different surgeons. We've gotten just voice of customer, you know, thoughts from. And ⁓ people were getting excited. They were getting as excited as I was. ⁓ and that's kind of really what led to the formation of the company where I brought in y you know, core members because ⁓ you know, I knew I wasn't smart enough to do this alone. ⁓ and I knew that it was just exciting and invigorating that I wanted to share it with others. I didn't want to feel isolated, like I was doing this by myself. I w you know, I wanted to be part of a team. and that really was October of twenty twenty four. And it's it you know, it s we incorporated in May of twenty twenty four and that that anniversary is coming up. and it's incredible to me what we have been able to do in two years. ⁓ we've done ⁓ animal studies, we're close to design freeze. We're going to First in Human in India and ⁓ in August. and it has been a true testament to a small group of people. Who are passionate ⁓ and dedicated and what they can achieve. ⁓ speaker-0: What an amazing story. And I I'd like to just zoom out a little bit and and talk about the condition that you're looking to address. So if we think about it from a worldwide perspective, approximately, I believe, 250,000 people die from an aortic aneurysm or aortic dissection. What about these conditions make them so hard to address that the standard is such that you have to go through bypass and stop circulation? and makes it so urgent to treat. speaker-1: Yeah, absolutely. I think those are great questions. and ⁓ so if I could break those down into two different things, I think one is how what about this operation? Like what are the anatomic differences that change how we do this? And the main reason is when you think about routine cardiac surgery, we can put a patient on bypass and then we do something called an external cross clam. Which allows the blood to go to the body and the brain, but it doesn't go to the heart. And we can operate in and around the heart or a portion of the aorta with when we cut it open, there's not five liters a minute of blood coming into our face. The challenge with aortic surgery is because of where the aorta is, we cannot place this external cross claim. So if we were to provide this five liters a minute of blood flow that the body and brain needs, the minute you cut into that aorta that needs to be replaced, it would all come out. ⁓ you wouldn't be able to see, you wouldn't be able to keep up with that blood flow. ⁓ and it is all from that one anatomical constraint of we have to operate, you know, through what we call median sternotomy, like the normal operation you see for every cardiac surgery. But the the aorta we need to clamp is not accessible through that incision. It's you know it's only accessible if your body's ⁓ on its side. So that is really what led to the only way we can operate on this part of the body is by literally taking out all of the blood flow ⁓ i that a human being has. And the only way to make it survivable is. is to cool a body down where it doesn't need any blood flow for that period of time. And that's the best that we've been able to do for a very long time. And what surgeons have found, you know, over 72 years is people do better when their organs get blood flow the whole time. People do better when you don't cool and rewarm them. But there's been nothing that's been available on the market. That has been made for this purpose. So, what surgeons have done is found essentially off-labeled devices that they've used to address brain perfusion, but really nothing for lower body perfusion or abdominal organs or kind of the rest of the organs. Right. And because of that, most of the world has been left. with the standard of care being this ridiculous process, right? Whenever I describe it to a patient, their eyes go, What are you gonna do to me? and so that is really the the crux of why we have to do circulatory arrest. And I I think what the the elica device does is it takes away this need to actually be able to see or feel the the A or to to clamp it because we're not doing it externally. We're doing it endovascularly. ⁓ so it's using kind of all of these endovascular innovations and techniques and using it in open surgery. speaker-0: Mm. So it's endovascular, it's not external, and it's essentially isolating the stoppage of blood circulation to the area where you're operating. speaker-1: Exactly. Yes. A very simple solution and a very common sense solution ⁓ for for bettering patient outcomes. And I think to kind of address what you were ⁓ talking about, just the pathology in general, why is this so deadly? Why is it so silent? So the aorta, right, is the most critical organ in the body. It is what y everything. depends on for blood flow. And the way that we get to what we call acute aortic syndromes, whether it be rupture or dissection, usually starts with something called an aneurysm, right? So dilation of the aortic wall. And just like a balloon, as the balloon gets bigger, the walls get thinner. And that's the same thing with the aorta. So now you have a thinner, weaker aorta that's still Has, you know, five and a half liters a minute of blood flow going through it at a pulsatile state. And at some point it becomes too weak to hold any of it in, and it just ruptures widely. And that's near a hundred percent mortality, right? Whenever it happens. Or there's ⁓ something called the deception that happens, which is a small tear starts, and once that tear starts, it spreads, it spreads all throughout the body and then becomes kind of two channels of blood flow. And so that outside wall becomes incredibly weak and the blood keeps getting pushed as a clot starts to form. And so the reason it's so deadly is because every part of your body is affected by this, including specifically your heart and your brain. speaker-0: Yeah. Yeah, because we're talking the largest blood vessel in the body. And essentially that becoming dissected and essentially at that point losing all blood flow, circulation, perfusion to the most critical organs in the entire body. speaker-1: Exactly. Exactly. And the horrible part about this is it is so silent until y you know, it's basically you can't help patients anymore. And ⁓ there's no there's no pain, there's no there's no warning sign. No s and so how we no symptoms at all. speaker-0: Thank you. speaker-1: And how we find patients before these dissections happen, ⁓ you know, patients with aneurysms is really CT scans and we see this incidentally. And so that's been the w you know, the great thing about TAVER CT scans or now coronary CT scans that are screening for coronary disease or, you know, trauma if you get a C T scan for trauma or for a lung cancer screening. We're finding more and more of these patients, but the the unfortunately the threshold for operation hasn't changed, mainly because it's such a high risk operation. speaker-0: Right. And I think that's a critical aspect is that even if you're picking it up by incident, I can imagine from your perspective as a cardiac surgeon, you're looking at that aneurysm and you're trying to understand and determine has it crossed the threshold where intervening now is more likely to address without creating residual issues. speaker-1: Exactly. It's taking a patient that is, you know, smiling, happy, can do all the things, isn't limited, and saying, We think this is your risk of rupture or dissection, but let me put you through an operation that's a nine percent chance of dying, an eight percent chance of stroke, a six percent chance of kidney injury. Which is incredibly difficult on a surgeon, right? Taking it's one thing to fix something that you see as hurting somebody. It's a whole nother thing to do something preventative because you think something bad is gonna happen. and there's a lot of ⁓ so there's surgeons that have built these practices, lower their operative mortality because they're doing more and more and more of it. But those are very few centers. So for example, in the United States, really forty-five centers do seventy percent of elective cardiac ⁓ aortic surgery. Forty cent forty-five centers do seventy percent of elective aortic surgery. And if you look at that worldwide, just kind of coming back to our resource and inequity in India. Right. They do the largest number of coronary artery bypass grafting there is, and you know, mainly because of the population. But there's really about six aortic centers in India. Six. Digit. speaker-0: Six or a population over a billion population. Yeah. Wow. speaker-1: And it's not because the operation is hard. It's because the way that we do it, this deep hypothermic circulatory arrest is such ⁓ a resource intensive thing where hospital needs to be all in. Right now it loses in the United States and in Germany, hospital loses twenty thousand dollars per patient where they do this type of operation. now in the US, right, these these hospitals are able to make up for it with other cardiac surgical operations that are actually revenue profitable. but ⁓ you can imagine in lower resource countries they're not able to make up that that that bandwidth. speaker-0: Right. And and so you are implicating two things that are super powerful. The first one is the ability to lower the threshold to say that maybe we can reduce the risk of intervening. And by reducing the risk of intervening, we are more convicted to intervene earlier and therefore change the survival trajectory of this condition. So move the threshold, make it lower. And the second one is perhaps we can impact the workflow in a way that makes this more of a economically feasible operation for many more people. speaker-1: Absolutely. I think that's a very insightful way to summarize that. ⁓ and ⁓ we have a long ways to go in aortic pathology. Right. And even though the experts kind of know ⁓ right now our indication is a five centimeter diameter for when we offer an operation, but we know that in a four foot eleven female Weighting at five centimeters is not a good idea. Just the the ratio of aortic size to to body height. And so what is happening now, because we're aiming for that risk benefit. And like most things, they're based off of white men, right? Studies and white men. So we know that women who show up are sicker. And Have worse outcomes, even if they have operations, because they should be getting an operation that's more individualized to them. But right now we don't even have the bandwidth to think about that because the only thing that we have to offer is so high risk. It's like when you only have a hammer, what can you do with a screw? Right. speaker-0: Yeah. Yeah. Yeah. And I mean certainly if you have a certain threshold you're waiting for before you intervene, and that's this five to six centimeters, and there's patient populations, that could be potentially too late. so you know, being able to lower the threshold for for all will maybe improve outcomes for for some that have maybe waited too late ⁓ for for a very long time. So I'm curious. I mean, you there's a big difference between seeing the problem. All clinicians see problems and issues. There's a big difference between observing, seeing that problem and deciding you're gonna rebuild an entire workflow around it. What gave you the condition the conviction ⁓ that you could do this, that this wasn't just maybe an incremental improvement or just something that you're seeing, but that you could actually do something to improve potentially the standard of care? speaker-1: Yeah. ⁓ I I think for me it was ⁓ years of just kind of anecdotal experience. So I did all my training at Mayo, an academic place that, you know, people from all over the world come to and everybody there ⁓ believes they're offering the best care possible and think of it as their onus to deliver that care. and so we took risks. Right. We did the things that most others couldn't ⁓ or not couldn't, but wouldn't, right? ⁓ because we had the safety net of salvage, of resources, of everything that was available to be able to bail a patient out of a bad situation if they got in one. And I went from Mao to ⁓ standalone heart hospital in Sioux Falls, South Dakota. And the main difference that I saw there were was two things. ⁓ one, it was the same drive, right? That same incredible drive of the physicians and the nurses and the healthcare workers around me, of wanting to do the absolute best for their patients. Yes. But knowing that if their patients became ill, became, you know, in those dire straits. there was a lot there was a line at which, you know, we didn't have ECMO, we didn't have all of the resources of Mayo Clinic to be able to get this patient through. And what that resulted in is me seeing my senior partners who I thought were some of the best surgeons in the world, right? And I had just come from Mayo Clinic. And here were there these two surgeons in Sioux Falls, South Dakota that I thought were just technically amazing and excellent, but would electively not do circulatory arrest cases because they didn't think that we could get these patients through at this hospital. And it, you know, I said to my well, that's not a big deal, right? They'll just go to Mayo. It's three and a half hours away. It's not a big deal. speaker-0: Right. speaker-1: And that is not what happened. I would say 80% of every patient that I saw there in Sioux Fall, South Dakota, did not want to leave their hometown. They didn't want to leave their family. They didn't even if they knew that meant they could die from this condition, if we didn't offer the operation there, they were just gonna sit and wait. Or just we were gonna observe it. And if something happened, that's what was going to happen. So this whole idea, and I think there is a bias at academic institutions that why are you doing these large things at these community hospitals? Why aren't you just referring out or sending? It's because patients don't want to go. It's because patients can't afford to go. Right. And it's it's because healthcare, especially cardiac surgery, is an incredibly stressful time in a human being's life, right? And not having that support structure is a terrible thing. So all of that, and sorry I'm kind of droning on here, but all of that was these kind of excuses we had made for why we weren't offering these operations and why they weren't available to people, were just kind of coming back full circle to me. Yeah. And this was the easiest thing that I felt like I could fix. Here is this thing we know is not a good idea as a cardiac surgeon. You don't even need to be a cardiac surgeon to understand this, right? Like it's not good for your body to not get blood flow. And the only reason that we're not we're doing it this way is because we don't have the right tool available to us as a surgeon. And it's not a You know, it's not Taver, right? It's not rethinking what is possible. It is not this is ⁓ you know, I'd heard from somebody kind of innovation happens in what that next step is, right? It's not that eighth step, it's that next step sometimes. And it it you know, it was one of those things it it felt doable, it felt like something I could create and using a human being the next day and it was safer than what we were doing now. Yeah. and I think it was also a time in my life where I just didn't feel a lot of control over a lot of things. I was a young, you know, I still a a mother of young kids and ⁓ just personally and this felt like something that I could change for the better. ⁓ and I think that's always something that's driven me. ⁓ speaker-0: Yeah. speaker-1: And maybe coming back to I am as stubborn as they get. So th I think that also helped. speaker-0: Well, you're making an incredibly compelling case. I can only picture you in pitches when you're when you're looking at fundraising. Must be very, very effective. But to that end, I am curious because it is I mean, it makes so much sense based on what you've described and clearly having the clinical experience makes it even that much more compelling. That being said, as you mentioned, it's not it's not a taver, it's not sort of Completely rethinking a procedure and unlocking a new patient base that maybe hasn't even had a treatment option before. And so in that sense, while I I believe it has the ability to be transformational in the field, you probably have a lot of people who look at this and say, Well, it sounds incremental and it's already part of a procedure. How does it get reimbursed? And all these questions are those you get the question, you know, is this too simple? Sometimes ⁓ when you're looking for for investment. speaker-1: Yeah. ⁓ the question actually along those lines is why hasn't somebody done this before? Which is I think what you're alluding to. And the answer to that is people that truly understand this procedure enough to be thinking about what can be changed. There's forty three hundred of us in the country. And most of us are on call every third day. Right. ⁓ and we're busy. So to have the bandwidth to say, I am taking this on in that 4,300 person patient pop, you know, person population, I think that's why it's taken so long, right? Somebody has to have had just enough ⁓ to want to take the next step. And I think if you look at kind kind of cardiac surgical innovation. Right. We're a young field. ⁓ really only seventy-two years old. And it's amazing. Like bypass, right? Growing up at Mayo, we saw the Kirkland bypass machine in the basement and we walked by it every day going to the research lab. and it that was possible. Because most cardiac surgeons had a lab on the side and you know, it was it was such quick pace of iteration. Yes. And everybody understood the absolute critical need to get cardiac surgery safer and actually possible. And so the pace of innovation in the early days of cardiac surgery is something that I don't think we'll ever see repeated. And then with Taver and Tvar and stents all coming really from cardiac surgeons, right? Initially, like just the ideas. We started as surgeons thinking about not how can we make this operation better, but how can we really take the physiology that we kind of change and change that through minimally invasive ways. So there was this point, right, in the late 1990s, early 2000s. Where when I told somebody I wanted to be a cardiac surgeon, they would say, Well, you're not gonna be able to feed your kids. Right. They everybody thought cardiac surgery was a dying field. And if I wanted to be able to make a living, I should become a cardiologist. And that is truly how the market has gone. If you look at med device and innovation and and ⁓ venture capital and all of that, it's been through interventional and endovascular methods. And I really don't think it's been until very recently that people are realizing even with minimally invasive options available, you always need cardiac surgery as a backstop because the minimally invasive methods f it can either fail, are not the right thing for everybody for the long term option. And what that has led to is cardiac surgery becoming more complex, scarier, harder. speaker-0: Yeah. speaker-1: and kind of less volume for surgeons, right? And and volume is what makes outcomes better. And so speaker-0: Created a interesting paradox, or at least I've heard it described as a paradox where you have all of this investment focus volume headed into interventional cardiology. And essentially those procedures start to become those that are less risky. You have maybe lower volume than going to cardiac surgery, and those are more complex, more risky to your point. So what we actually need is even more emphasis on cardiac surgery and how do you bridge that gap? How do you solve that paradox? One of the ways that you do it is by advancing the approaches in cardiac surgery so that you can sort of democratize the field in a way where you don't have to be one at forty five centers in the country, but it opens it up for the other thirty percent that don't have access to that. speaker-1: I think you said the absolute right word. How do you democratize aortic surgery? Right? And that's from taking something that is dangerous out of people's comfort zone and making it look like something that they do everyday routine. speaker-0: And and so you talked about that how you addressed the question, you know, why hasn't someone done this before? And I thought that was a fantastic, fantastic insight ⁓ about the forty three hundred. How do you think about the other side of the equation when maybe you have a cardiac surgeon who's done it one way their entire career? ⁓ what do you think has to be true for a cardiac surgeon to actually change how they operate? speaker-1: Yeah. For us it's all about outcomes, right? It's about the data. and I think there's one other thing here and I'm not trying to make light of it, but we have egos as cardiac surgeons, right? And one of the biggest kind of feathers in our cap we talk about Cross cleave time, we talk about time on bypass and we talk about how long it took us to do an operation. Cause, you know, it's always been the faster you are, the better you are. I'm not sure that's completely true, but it you know, that's been the metric. and so if you have your forty-year-old junior partner in the other room using our device who's done in four hours. And you're the older senior partner who's doing it the standard of care, you know, circulatory arrest way, and you've been there all day, that changes very quickly. just the ⁓ the patient there's the patient outcomes, right, that we're hoping to prove out with the with the clinical, like take our theory and make it data reality. But there's also this huge driver of operating room time that is such a huge differential that I think is a much bigger driver for for us ⁓ than it is in other kind of changing enabling tools. speaker-0: Right. And and so you you've made tremendous progress over the last two years. Congratulations on your your two year anniversary, but by the way, as a as a company, nearly three years since since concept. And you have a tremendous concept. You're you're headed towards design freeze, you're headed towards first in human, all very exciting. You know to be able to advance the standard of care, you have to advance and show outcomes. What are you hoping to see through clinical study and evaluation and are there things that you can identify and see acutely, that would be enough, or do you need to see something more in the chronic phase? speaker-1: No, ⁓ really most cardiac surgical metrics are a 30-day metric, right, through the Society of Toracic Surgeons database. And in here we're really ⁓ looking at acute outcomes. So our clinical trial would be focused on kind of a combined mortality and morbidity endpoints. So, you know, operative and in hospital mortality, stroke risk, kidney injury risk. ⁓ and what we're also doing or planning on doing. Is using those metrics to also build out that economic model that we've been focusing on for hospitals. So really keeping track of not only operating room time, but also ICU days, readmissions, all the things that move the mark for hospitals. So that when we are commercializing, we're not going to a value analysis committee and saying, we think this will happen, we will have clinical trial data that shows, you know, real world economics for a hospital. speaker-0: Very, very exciting. And I I'm just curious, how do you balance all the clinical work you have? You obviously have a very busy personal life and then you're building a company. How are you balancing all of this? speaker-1: I may be one of the most spoiled human beings on earth. I just incredibly supported in all the ways. ⁓ personally I'm an only child and my parents ⁓ who I think are looking for, you know, the time they didn't have with me when I was growing up since I was with my grandparents, who live down the street. ⁓ they are, you know, they they're our village for our children. my husband is just incredibly supportive. ⁓ And you know, he's has the flexibility to work remotely and just ⁓ you know, just so supportive. on the other kind of the opt-in side, the team that we've been able to build is I mean, I think I talked to Laura, our CEO, probably more than anybody else. Like she knows everything that's happening with my kids, my you know, my hus just everything in my life. She is the first person ⁓ and you know, one of my strongest advocates. and I'm so lucky, ⁓ you know, people talk about how entrepreneurship and building, you know, even the word of solopreneur, right? and Laura, you know, Laura and I have been friends for a while and I approached ⁓ her about coming on ⁓ is as CEO for the company while we were on a trip ⁓ together in Albuquerque, New Mexico, we were going to the Hotter Balloon Festival. And I just, you know, sprang this on her while our kids are all running around. We're sitting eating breakfast. And she almost accepted on the spot. And her absolute trust in the vision and that we were gonna make this happen. ⁓ you know, to be full time, with you know, with somebody who's never done this before, is figuring it out. ⁓ I can't tell you how humbling that is. And whatever the word is that is opposite of isolating, ⁓ which I should be able to come up with, but speaker-0: You have a great you've built a great community and it it what's so inspiring is they seem to have equal vision for for what you're doing in each of those domains of your life. And I think that is the more compelling than being the so-called solopreneur. ⁓ you've also built an impressive group of advisors, and I can imagine going from the clinic into building out a business. building a group of advisors that you can rely on that have been there and done that is important. How did you go about selecting the people that you've wanted to get involved with this effort? speaker-1: Yeah. I I think I took the the least selective way that you can do that, right? I I said, I don't know what I'm doing. I'm gonna meet as many people as I can. I will take a phone call, take a Zoom meeting, take an in person meeting with anybody that will meet with me. And that resulted in Man, I can't I don't even know the number. I have met over 1,500 new like people. It was an incredible experience. And I don't think, you know, you don't often get to do that as a 41 year old, right? You don't get to just meet new people and establish these relationships. And at the end of the day, it wasn't me pitching to them. ⁓ I think what became the normal, which in medicine isn't true, right? We don't n I don't think we are taught very well how to network or how to build relationships. ⁓ but it was just tell me what you want. Like as a human being, what are you trying to achieve? What are you trying to build? ⁓ which is which I think is the gold in the med tech environment, right? And when you're ⁓ and so ⁓ It was all just very natural. It was in talking with lots of people who introduced me to other people who then naturally were interested in this disease or disease processed or were compelled for the reasons of why I was doing it. and it really shared their experience and vision very freely. ⁓ without ⁓ kind of like there was no quid pro quo, there was no like ⁓ it was ⁓ just people were so generous i in all the ways. And i you know I think these advisors that we've been able to ⁓ just have the privilege of working with, they not only have a personal connection to the field, right? Or or to the disease process, but they also, I think felt a personal connection with either me or Laura or or that. Like that was also quite important. And so we were it was about you know that first and kind of everything else second. You know, and perhaps maybe that wasn't the right way to do it. I think You know, sometimes I get the advice like think about what they look like on your pitch deck first and then go find them. Is that a piece of advice I've gotten, which is maybe the opposite of what I've done? but ⁓ yeah, I I I think it has been kind of just organic meetings of one person that has led us to another and just aligned interests ⁓ that's really ⁓ you know, gotten us the our backbone. Right. Our our support. speaker-0: Yeah, I think what you've tapped into something really powerful in the med tech community, which is when you have a vision, going to the community, sharing the vision and just saying, What can I learn from you? versus I'm targeting this person for a very specific reason. It's just building the network under the context of I know where I want to go, broadly speaking. I have a vision and I know there's something I can learn from you. What's your perspective? What is your feedback? And I think the generosity and the engagement you get with that approach is so powerful. And then you start to see the puzzle pieces start to come together over time in terms of what level of engagement you want to get from them, whether it's advisor level or or something else. And I think it's just a really powerful way to go about it because what you find is people match their passion and their experience to your vision. And in those cases there's a place for them. speaker-1: Yeah, absolutely. ⁓ and that has I think helped me grow as a human being because I with the stubbornness also as an impatience. And this has taught me patience, right? That you you know there's all these things that need to be done and kind of roles that need to be filled. And it's not, you know, trying to pluck people and put ⁓ in these roles, but kind of having this organic maturement of what those rules look like as the right people come across. speaker-0: Right. So so what's next for Octon? We know that you are headed towards design freeze and first and human. Are you in the process of fundraising? And what is the ultimate vision for where all this could go, speaking of vision? speaker-1: Absolutely. ⁓ so we are actually getting close to wrapping up our seed round, ⁓ which gets us through first in human and very close to FDA submission. And ⁓ then, you know, really kind of ⁓ one other larger raise after that ⁓ to f ⁓ our series A would be to fund our that clinical trial I was talking about, ⁓ for that data. And we've already, you know, been in talks with potential strategic acquirers. ⁓ actually probably did that before I did anything else. ⁓ mainly because for me, understanding the cardiac surgical market as I do as an end user. It's really hard to come in as a company with one or two products and go up against, you know, Medtronic or go, you know, go up against the behemoths. And I see that every day, right? I see that like big contracts for a hospital matter. So ideally, we build our devices, our the Elka device specifically, to a point where it is clinically s valuable. Right. The all the engineering, all the clinical data, the the science has been thought through. And when it comes to the true commercialization aspects of it, we're acquired and kind of get to plug and play so that it gets to the most amount of patients as quickly as possible. and I think that is the vision for us. And it's can we get it to the right partner so that it gets you know, this gets the most amount of utility. ⁓ and I think at the end of the day, decision making at that capacity is what probably yields in the best financial results. speaker-0: Right. Yeah. You you deliver the outcome and then a partner potentially delivers the reach and that's how we get it out to the most amount of patients possible. It's a powerful combination. So what I'm curious, what advice would you give to other physicians who are contemplating going down this road of building a technology that could advance medicine? speaker-1: Yeah. I will say the hardest thing is leaving your ego at the door. you know, I think physicians in general are incredibly intelligent. we've risen to the top of whatever, right? to kind of get to where we are. And I had no idea what I didn't know and what I don't know every day. So it is relying on others and having the humility ⁓ to step back and say, I think you are better at this than I am. How can you help me do this? ⁓ and I think that is the most important thing that I would say for really any technical founder, right? But especially physicians. ⁓ it is at the end of the day, it's not about you. It's it's about the company, it's about the product, it's about the patient. And keeping that as a guiding principle, ⁓ it I think makes this a a much better journey. speaker-0: Great advice. Fantastic advice. Well, this has just been a wonderful conversation. I feel very fortunate because I know how busy you are with all the domains that you're engaged with. But it also just is really striking to me to think about the fact that the advent of cardiac surgery goes back to the nineteen fifties. So with ⁓ with bypass and now we're, you know, as you mentioned, seventy some years in, I don't know how old's ⁓ the age of your grandfather, but that he would have lived through potentially that entire arc and then be at a place where you're now advancing it or looking to advance it to the next level. It's incredibly powerful to think about that. speaker-1: Yeah, I I hadn't actually thought about it that way, but you're absolutely right. Eighty four speaker-0: Yeah, that's incredible. So thank you so much for for joining. This was a great discussion. Wish you all the best with year round and ⁓ we look forward to looking at the the data and the announcement coming out from your for first in human experience. speaker-1: Amazing. Thank you so much for your time. It was a lovely conversation. speaker-0: And thanks to all of you for joining us on Powering the Future Within. If this conversation inspired you, follow the show and share it with your med tech community. I'm Omari Baugnight. Stay inspired and keep innovating.